Benchmark reiterates Live Nation stock Buy rating after jury verdict By Investing.com

Live Nation faces continued antitrust risk after a jury found it overcharged customers by $1.72 per ticket between May 2020 and 2024, though Benchmark reiterated a Buy rating and $190 price target versus the stock at $155.82. The immediate focus shifts to Judge Subramanian’s ruling on damages and potential remedies, including a possible Ticketmaster breakup, which the analyst считает unlikely after the DOJ settlement. Other firms remain constructive, with targets ranging from $192 to $206, partially offsetting the legal overhang.

Analysis

The market is treating this as a legal overhang, but the more important second-order effect is that the remedy phase creates a long-duration multiple cap rather than an immediate earnings hit. Even if damages are manageable, the possibility of structural remedies keeps a higher equity risk premium in place, which is why upside toward consensus targets may be slower than the analysts imply. In practice, the stock can drift on headline relief, but every new court milestone reintroduces a distributional debate between operating strength and regulatory fragility.

The real winner here is the live-events ecosystem outside the platform bottleneck: venue operators, promoters with alternative ticketing rails, and secondary-market intermediaries can all gain bargaining leverage if customers and artists demand less concentrated routing. That said, a forced separation would be messy and likely years away, so the near-term impact is more about contract renegotiation and pricing concessions than a clean breakup. This creates a subtle margin squeeze risk: even without divestiture, legal scrutiny can force higher compliance costs, lower take rates, and more generous commercial terms to preserve artist relationships.

Consensus seems to be underweighting the asymmetry between headline risk and actual cash-flow durability. The business can remain profitable and still deserve a lower multiple if the market believes antitrust entropy will persist; that is especially relevant because the next 6-12 months are about remedies, not liability discovery. In our view, the stock’s upside is probably more tactical than fundamental until the court narrows the remedy path, making this more of a trading vehicle than a clean long-duration compounder right now.

Key Decisions for Investors

• Hold a tactical short or underweight in LYV into remedy hearings over the next 1-3 months; risk/reward favors a lower multiple compression if judges keep structural remedies alive, even if breakup odds remain low.
• If already long LYV, buy downside protection via 3-6 month put spreads struck around current levels; this limits bleed while preserving upside if damages/remedies prove modest.
• For relative value, pair long a less-regulated live entertainment beneficiary or venue-linked name against short LYV to isolate idiosyncratic antitrust risk; expect the spread to widen if court commentary turns hostile.
• Do not chase analyst-target upside immediately; instead wait for post-ruling volatility to reset implied risk premium before initiating longs, since the stock can re-rate only after remedy uncertainty narrows.